CancerDrs

Cervical Cancer clinical trials in Oregon

22 actively recruiting cervical cancer trials at 13 sites across Oregon.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting NIH

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061977
Sites in Oregon:
  • Clackamas Radiation Oncology Center — Clackamas, Oregon
  • Providence Newberg Medical Center — Newberg, Oregon
  • Providence Willamette Falls Medical Center — Oregon City, Oregon
  • Legacy Good Samaritan Hospital and Medical Center — Portland, Oregon
  • Providence Portland Medical Center — Portland, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in Oregon:
  • Saint Alphonsus Cancer Care Center-Ontario — Ontario, Oregon
  • Providence Willamette Falls Medical Center — Oregon City, Oregon
  • Providence Portland Medical Center — Portland, Oregon
  • Providence Saint Vincent Medical Center — Portland, Oregon
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Academic/Other

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…

Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in Oregon:
  • Clackamas Radiation Oncology Center — Clackamas, Oregon
  • Providence Newberg Medical Center — Newberg, Oregon
  • Providence Portland Medical Center — Portland, Oregon
  • Providence Saint Vincent Medical Center — Portland, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in Oregon:
  • Oregon Health And Science University — Portland, Oregon
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

An open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ …

Sponsor: BioNTech SE
NCT ID: NCT04534205
Sites in Oregon:
  • Providence Cancer Institute — Portland, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07216703
Sites in Oregon:
  • Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8007) — Eugene, Oregon
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Oregon:
  • Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
  • Saint Charles Health System — Bend, Oregon
  • Clackamas Radiation Oncology Center — Clackamas, Oregon
  • Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
  • Bay Area Hospital — Coos Bay, Oregon
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Oregon:
  • Saint Charles Health System — Bend, Oregon
  • Clackamas Radiation Oncology Center — Clackamas, Oregon
  • Providence Newberg Medical Center — Newberg, Oregon
  • Saint Alphonsus Cancer Care Center-Ontario — Ontario, Oregon
  • Providence Willamette Falls Medical Center — Oregon City, Oregon
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04671667
Sites in Oregon:
  • Clackamas Radiation Oncology Center — Clackamas, Oregon
  • Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
  • Providence Newberg Medical Center — Newberg, Oregon
  • Providence Portland Medical Center — Portland, Oregon
  • Providence Saint Vincent Medical Center — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…

Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Oregon:
  • Providence Cancer Institute Franz Clinic — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

Sponsor: GV20 Therapeutics
NCT ID: NCT05669430
Sites in Oregon:
  • Oregon Health & Science University — Portland, Oregon
View on ClinicalTrials.gov →
Phase 2 Recruiting Federal

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

Esophageal cancer, which has a low 5-year overall survival rate (\<20%) is increasing in incidence. Previous studies have shown that Hedgehog, AKT, and angiogenic signaling pathways are activated in a significant number of esophageal cance…

Sponsor: VA Office of Research and Development
NCT ID: NCT05563766
Sites in Oregon:
  • VA Portland Health Care System, Portland, OR — Portland, Oregon
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

This research is being done to see if it is safe to give investigational combination of study drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable (removable) newly diagnosed or recurrent metastatic SCCHN…

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT05977907
Sites in Oregon:
  • Providence Cancer Institute — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Oregon:
  • Providence Cancer Institute Franz Clinic — Portland, Oregon
  • Providence Oncology and Hematology Care Clinic - Westside — Portland, Oregon
  • Providence St. Vincent Medical Center- Investigational Drug Services — Portland, Oregon
  • Providence St. Vincent Medical Center — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors. This study is …

Sponsor: Pfizer
NCT ID: NCT05355701
Sites in Oregon:
  • Providence Cancer Institute Franz Clinic — Portland, Oregon
  • Providence Portland Medical Center — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of MGC026 in Participants With Advanced Solid Tumors

The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tu…

Sponsor: MacroGenics
NCT ID: NCT06242470
Sites in Oregon:
  • Providence Cancer Institute — Portland, Oregon
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Oregon:
  • Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
  • Saint Charles Health System — Bend, Oregon
  • Clackamas Radiation Oncology Center — Clackamas, Oregon
  • Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
  • Bay Area Hospital — Coos Bay, Oregon
View on ClinicalTrials.gov →
NA Recruiting Network

A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

This is a randomized controlled trial to compare survival for patients who undergoe robotic assisted laparoscopy versus open hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.

Sponsor: GOG Foundation
NCT ID: NCT04831580
Sites in Oregon:
  • Legacy Good Samaritan Medical Center-Gynecological Oncology Group — Portland, Oregon
  • Providence Center Institute Franz Clinic — Portland, Oregon
  • Legacy Meridian Park Medical Center-Legacy Medical Gynecologic Oncology — Tualatin, Oregon
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Oregon:
  • Massive Bio SYNERGY-AI site — Portland, Oregon
View on ClinicalTrials.gov →
Recruiting Industry

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, …

Sponsor: Adela, Inc
NCT ID: NCT05366881
Sites in Oregon:
  • Oregon Health Sciences University — Portland, Oregon
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07